<DOC>
	<DOCNO>NCT00005614</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness gemcitabine treat elderly woman metastatic breast cancer .</brief_summary>
	<brief_title>Management Metastatic Breast Cancer Frail Patients</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety efficacy gemcitabine treatment elderly woman metastatic breast cancer . II . Evaluate quality life patient . OUTLINE : Patients receive gemcitabine IV 1 hour weekly 7 consecutive week 8 week course . Treatment continue weekly 3 consecutive week 4 week course absence disease progression unacceptable toxicity . Quality life assess prior treatment every 12 week . Patients follow every 3 month 2 year , every 6 month year 5 , annually thereafter . PROJECTED ACCRUAL : A total 40 patient accrue study 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Metastatic breast cancer Measurable disease No progression 3 different form chemotherapy Hormone receptor positive breast cancer must refractory least two form hormonal treatment ( include antiestrogen , aromatase inhibitor , and/or progestin ) unless life threatening metastasis ( e.g. , lymphangitic metastasis lung liver metastasis ) Must meet least one follow characteristic frailty : ECOG 24 Dependence least one activity daily live 85 History three fall past 6 month Mild dementia ( must orient time , space , location ) Three comorbid condition Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 65 Sex : Female Menopausal status : Not specify Performance status : See Disease Characteristics Life expectancy : Greater 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Neutropenia thrombocytopenia secondary myelophthisis breast cancer allow Hepatic : Increased bilirubin allow Renal : Renal insufficiency allow Cardiovascular : Congestive heart failure allow Other : No know allergy gemcitabine PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : See Disease Characteristics Radiotherapy : At least 4 week since prior radiotherapy bony area CNS metastases Surgery : Not specify Other : Concurrent bisphosphonates allow No concurrent participation investigational study</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>